Obsidian grants CEO options on 37,653 shares

Obsidian Therapeutics, Inc. granted Chief Executive Officer Madan Jagasia a stock option covering 37,653 shares of common stock on August 3, 2026.

Accepted by SEC EDGAR 08/05/2026 - 04:08 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Obsidian Therapeutics, Inc. granted Chief Executive Officer Madan Jagasia a stock option covering 37,653 shares of common stock on August 3, 2026. The option has an exercise price of $12.00 per share and expires on August 2, 2036. The underlying 37,653 shares vest and become exercisable upon the earlier of the one-year anniversary of the grant date or the company’s next annual meeting of stockholders following the grant date, subject to Dr. Jagasia’s continued service.

Insider Trade Summary

Grant/Award: 37,653 shares

Grant/Award 1 txn

Insider Jagasia Madan

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	37,653	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 37,653 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Key Figures

Options granted: 37,653 shares Exercise price: $12.00 per share Expiration date: August 2, 2036 +1 more

4 metrics

Options granted 37,653 shares Stock option grant to CEO on August 3, 2026

Exercise price $12.00 per share Exercise price of CEO stock option grant

Expiration date August 2, 2036 Expiration of CEO stock option grant

Underlying shares 37,653 shares Common stock underlying the option grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 12.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares underlying this option shall vest and become exercisable upon the earlier"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the Issuer's annual meeting of stockholders following the grant date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Obsidian Therapeutics (OBX) disclose about Madan Jagasia in this Form 4?

Obsidian Therapeutics reported that CEO Madan Jagasia received a grant of 37,653 stock options. These options relate to the company’s common stock and represent a compensation-related acquisition, not an open-market share purchase or sale.

How many stock options did the OBX CEO receive and at what exercise price?

CEO Madan Jagasia was granted 37,653 stock options with an exercise price of $12.00 per share. Each option is a right to buy one share of Obsidian Therapeutics common stock at this fixed price if and when the option becomes exercisable.

When do the newly granted OBX stock options to the CEO vest?

The options vest upon the earlier of one year after the August 3, 2026 grant date or the date of Obsidian’s next annual meeting of stockholders. Vesting is subject to the CEO’s continued service with the company on the applicable vesting date.

What is the expiration date of the OBX CEO’s new stock option grant?

The stock option granted to the CEO expires on August 2, 2036. After this expiration date, any unexercised portion of the option can no longer be exercised to purchase Obsidian Therapeutics common shares.

How many derivative securities does the OBX CEO hold after this transaction?

Following this grant, CEO Madan Jagasia holds 37,653 derivative securities related to this option. These correspond to 37,653 underlying shares of Obsidian Therapeutics common stock, subject to vesting and exercise conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jagasia Madan

(Last) (First) (Middle)

C/O OBSIDIAN THERAPEUTICS, INC.

1030 MASSACHUSETTS AVE

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Obsidian Therapeutics, Inc. [ OBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12	08/03/2026		A		37,653		(1)	08/02/2036	Common Stock	37,653	$0	37,653	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.

	/s/ Gabriela Morales-Rivera, Attorney-in-Fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)